Bioengineered Vaccine Adjuvants

生物工程疫苗佐剂

• 批准号: 6403321
• 负责人: MANSSUR YALPANI
• 金额: $ 24.61万
• 依托单位: BIOPOLYMERIX, INC.
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-07-01 至 2001-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6403321
• 关键词: Lyme disease; Neisseriaceae; antigen antibody reaction; bacterial vaccines; bioengineering /biomedical engineering; chemical structure; cytokine; glycolipids; histopathology; immunologic substance development /preparation; immunomodulators; laboratory mouse; macrophage; polymers; vaccine development

DESCRIPTION (Provided by Applicant): We plan to develop a novel family of vaccine adjuvants through bioengineering a microbial glycolipid. This polymeric material is generated as a secreted product from the bacterium, Acinetobacter calcoaceticus and in preliminary studies demonstrates exceptional adjuvant activity. To further explore this application, we plan to correlate structural features of the polymer with macrophage response in vitro and antibody response in vivo to a series of these analogs. The Phase I studies will determine if the nature of the macrophage response is structure-specific, and if so, which structural features are most important. These features will then be assessed in vivo in a murine Lyme vaccine model. To accomplish this goal we will generate a family of structural analogs using methods we have recently developed, and then characterize these analogs for selectivity of responses of macrophages in terms of cytokine release followed by antibody response in vivo. The outcome of Phase I will be a selection of the best few candidate structures to move forward into more detailed in vivo testing in Phase II. PROPOSED COMMERCIAL APPLICATION: The development of a family of structurally related vaccine adjuvants is of considerable relevance for establishing structure-property relations and tailored therapeutics.

描述（由申请人提供）：我们计划开发一个新颖的家族 疫苗佐剂是通过生物工程改造而成的微生物糖脂。这种聚合物 该物质是由不动杆菌细菌的分泌产物产生的 calcoacetus 并在初步研究中证明了特殊的佐剂 活动。为了进一步探索这个应用程序，我们计划将结构关联起来 聚合物体外巨噬细胞反应和抗体反应的特点 in vivo to a series of these analogs. The Phase I studies will determine if the 巨噬细胞反应的性质是结构特异性的，如果是这样，那么 structural features are most important. These features will then be assessed in vivo in a murine Lyme vaccine model. To accomplish this goal we will generate a 使用我们最近开发的方法的结构类似物家族，然后 描述这些类似物对巨噬细胞反应的选择性 细胞因子释放随后体内抗体反应。阶段结果 我将选出最好的几个候选结构以继续前进 more detailed in vivo testing in Phase II. 拟议的商业应用： 结构相关疫苗佐剂家族的开发具有重要意义 建立结构-性质关系和定制治疗的相关性。